Study Objectives: The aim of the study was to describe the clinical and polygraphical characteristics of narcoleptics, with and without cataplexy and to assess HLA predisposition across two different ethnic populations.

Design And Setting: Patients were 126 men and 58 women referred to the Montpellier Sleep Disorders Center (Mtp) and 12 men and 8 women referred to the Fort-de-France Sleep Disorders Center (FdF) (Martinique, a French West Indy island) with symptoms of narcolepsy.

Participants: Narcoleptics were included if they had both excessive daytime sleepiness and clear-cut cataplexy (for the group with cataplexy), a mean sleep latency of less than 8 minutes and at least two sleep onset REM periods.

Interventions: N/A.

Measurements And Results: Narcolepsy without clear-cut cataplexy was rare (12/172) in the Mtp population whereas it was as frequent as full-blown narcolepsy (10/10) in the FdF population. Comparison between narcoleptics with cataplexy from the Mtp and FdF populations revealed a younger age of onset, a trend towards more severe sleepiness and lower frequency of cataplexy in Martinicans. Comparison between narcoleptics without cataplexy from the Mtp and FdF population revealed a higher frequency of hypnagogic hallucinations and sleep paralysis and a trend towards more severe sleepiness in Martinicans. 4.2% of the Mtp and 15% of the FdF patients were negative for HLA DR2. However all of them were positive for HLA DQ1. Moreover, a tight association with HLA DRB1*1503 was observed in Martinicans in contrast with DRB1*1501 in the Mtp population. Association with HLA DQB1*0602 was observed in 99.4% of narcoleptics with cataplexy and in 89.5% of those without cataplexy.

Conclusions: Narcolepsy is a heterogeneous clinical syndrome, the more so as ethnic origins are considered. A modulating effect of HLA and non-HLA genes on symptoms disease may explain these differences.

Download full-text PDF

Source
http://dx.doi.org/10.1093/sleep/25.1.50DOI Listing

Publication Analysis

Top Keywords

narcoleptics cataplexy
16
ethnic origins
8
cataplexy
8
men women
8
women referred
8
sleep disorders
8
disorders center
8
clear-cut cataplexy
8
mtp population
8
fdf population
8

Similar Publications

Article Synopsis
  • Narcolepsy is a chronic condition marked by excessive daytime sleepiness and cataplexy, and sodium oxybate (SXB) has been identified as the only effective treatment for its symptoms.
  • The study reviewed five randomized controlled trials (RCTs) to evaluate the effectiveness of SXB in reducing cataplexy attacks and improving wakefulness while also considering its safety by monitoring adverse events.
  • Results showed that SXB significantly reduced weekly cataplexy attacks and improved outcomes on various tests compared to placebo, particularly at higher doses, indicating it is an effective treatment for managing narcolepsy symptoms with a reasonably safe profile.
View Article and Find Full Text PDF

Histamine, a neurotransmitter, plays a predominant role in maintaining wakefulness. Furthermore, our previous studies showed that histamine N-methyltransferase (HNMT), a histamine-metabolizing enzyme, is important for regulating brain histamine concentration. However, the effects of pharmacological HNMT inhibition on mouse behavior, including the sleep-wake cycle and cataplexy, in a mouse model of narcolepsy have not yet been investigated.

View Article and Find Full Text PDF
Article Synopsis
  • Tongkat Ali (TA) is a traditional herbal medicine that may improve energy, fatigue, and mood, and recent studies on mice show it can influence their sleep and activity patterns.* -
  • In wild-type mice, TA supplementation promotes better wakefulness and sleep regulation by increasing diurnal locomotion and temperature rhythms, leading to longer sleep and activity bouts.* -
  • However, in narcoleptic mice, TA's effects on sleep and wake cycles are minimal, indicating that while TA benefits normal sleep patterns, its impact may be limited for those with narcolepsy.*
View Article and Find Full Text PDF

Ageing-related modification of sleep and breathing in orexin-knockout narcoleptic mice.

J Sleep Res

July 2024

Laboratory of Physiological Regulation in Sleeping Mice (PRISM), Department of Biomedical and Neuromotor Sciences, Alma Mater Studiorum - University of Bologna, Bologna, Italy.

Narcolepsy type-1 (NT1) is a lifelong sleep disease, characterised by impairment of the orexinergic system, with a typical onset during adolescence and young adulthood. Since the wake-sleep cycle physiologically changes with ageing, this study aims to compare sleep patterns between orexin-knockout (KO) and wild type (WT) control mice at different ages. Four groups of age-matched female KO and WT mice (16 weeks of age: 8 KO-YO and 9 WT-YO mice; 87 weeks of age: 13 KO-OLD and 12 WT-OLD mice) were implanted with electrodes for discriminating wakefulness, rapid-eye-movement sleep (REMS), and non-REMS (NREMS).

View Article and Find Full Text PDF

Background And Objective: At present, the etiology of narcolepsy is not fully understood, and it is generally believed to be an autoimmune reaction caused by interactions between environmental and genetic factors. Human leukocyte antigen (HLA) class II genes are strongly associated with this gene, especially HLA-DQB1*0602/DQA1*0102. In this study, we mainly analyzed the correlation between different genotypes of HLA-DQB1*0602/DQA1*0102 and clinical manifestations in Chinese patients with narcolepsy.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!